Thelansis

Malignant pleural mesothelioma (MPM) is a highly aggressive cancer affecting the pleural surface, often stemming from prior asbestos exposure, typically manifesting around 40 years after initial fiber exposure. The majority of MPM patients initially present with breathlessness, chest pain, or both. Early-stage breathlessness typically stems from pleural effusion, evident in 70% of patients at presentation. However, as the disease progresses, pleural effusions tend to decrease, either due to medical intervention or obliteration of the pleural space by the tumor. Additional symptoms may include fatigue, anorexia, weight loss, sweats, and malaise. Histologically, MPM presents in four main sub-types: epithelioid, sarcomatoid, biphasic or mixed, and desmoplastic. The sarcomatoid variant is notably associated with the poorest outcomes, boasting a median survival of only 4 months. In contrast, the epithelioid sub-type offers the most promising prognosis, with a median survival of 13.1 months....

  Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. Most MPM cases are caused by exposure to asbestos, often occurring >40 years previously. Prognosis with MPM is poor, and median survival ranges from 8 to 14 months after diagnosis. Women have a better prognosis than men, but due to the occupational nature of the disease, there is a 4:1 male predominance. The four major histological subtypes are Sarcomatoid, epithelioid, biphasic or mixed, and desmoplastic. The sarcomatoid variant is associated with the worst outcomes, with a four-month median survival.   The incidence of malignant pleural mesothelioma (MPM) ranges between 9 to 23 points per MN elderly patient with a man and women of 5:1.2.   The competitive landscape of Malignant Pleural Mesothelioma (MPM) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelera...